Quantcast

Latest C-peptide Stories

2010-11-01 22:27:31

A drug in testing to treat atherosclerosis significantly inhibited growth of ovarian cancer in both human cell lines and mouse models, the first such report of a peptide being used to fight malignancies, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center. The study follows previous discovery by the same group showing that a protein called apolipoprotein A-I (apoA-I) in patients may be used as a biomarker to diagnose early stage ovarian cancer, when it typically...

2010-10-07 15:37:00

SAN MATEO, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced that Michael R. Bristow, M.D. Ph.D. has joined the Scientific Advisory Board overseeing the development of CD-NP, a dual natriuretic peptide receptor agonist in development for the treatment of acute decompensated heart failure. Dr. Bristow, a recognized leader in the heart...

2010-09-23 06:30:00

STOCKHOLM, Sept. 23 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today presented an analysis of baseline data from the Phase 3 DEFEND-1 clinical trial of otelixizumab in patients with autoimmune new onset type 1 diabetes. The analysis showed that fasting C-peptide, as measured by results from a single blood draw, were highly correlated with maximum stimulated C-peptide, as...

2010-09-09 06:13:00

SAN MATEO, Calif., Sept. 9 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that Joshua Kazam, Chief Executive Officer, will present at the Rodman & Renshaw 12th Annual Global Investment Conference on Tuesday, September 14, 2010 at 2:00 p.m. (Eastern Time) at the Palace Hotel in New York City, New York. About Nile Therapeutics Nile Therapeutics, Inc. is a clinical-stage...

2010-07-22 06:30:00

SAN FRANCISCO, July 22 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced the appointment of Richard B. Brewer as Executive Chairman. With over 35 years of biotech and pharmaceutical industry experience, Mr. Brewer brings a wealth of operational, financial, and business development expertise to Nile. "We are extremely pleased to welcome Mr. Brewer to our...

2010-07-21 10:29:00

NEENAH, Wis., July 21 /PRNewswire/ -- A scientific journal, Phytotherapy Research (May 17, 2010), has reported findings from research teams at King's College London and at Burdwan Medical College, J. B. Ayurved College and Calcutta University (West Bengal). The conclusions confirm the earlier findings of Ayurvedic-Life that the patented Gymnema sylvestre extract, OSA(TM) (Om Santal Adivasi), stimulated insulin secretion from human islets in vitro and in vivo. They also confirmed earlier...

2010-06-28 06:00:00

ORLANDO, Fla., June 28 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today presented an analysis of baseline data from the Phase 3 DEFEND-1 clinical trial of otelixizumab in patients with autoimmune new onset type 1 diabetes. The analysis showed that higher C-peptide levels had a statistically significant correlation with a decrease in two distinct measurements of glucose...

2010-06-21 07:00:00

CRANBURY, N.J., June 21 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results of preclinical studies in respiratory tissue with PL-3994. In rat, guinea pig and human tissues, PL-3994 produced potent relaxation of isolated airway smooth muscle, indicating that PL-3994 may be a potent bronchodilator in humans. PL-3994 is a proprietary peptide mimetic that binds and activates natriuretic peptide receptor A, a guanylate cyclase. Naturally occurring...

2010-05-26 08:19:00

JERUSALEM, May 26, 2010 /PRNewswire-FirstCall/ -- - Study Data Shows ORMD-0801 Resulted in Glucose and C-Peptide Reduction Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of alternative drug delivery systems, announced today that the paper entitled, "Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects," authored by Dr. Roy Eldor, Dr. Miriam Kidron and Dr. Ehud Arbit, was accepted and...

2010-05-11 08:03:00

CRANBURY, N.J., May 11 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its third quarter, fiscal year 2010 financial results on Thursday, May 13, 2010 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 13, 2010, which will include discussion of the results of operations in greater detail and an update on corporate developments. Schedule for the...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related